Headlines
Trump says price of Ozempic will be lowered
Published by Global Banking & Finance Review®
Posted on October 16, 2025
2 min readLast updated: January 21, 2026
Global Banking & Finance Review®
Company
Published by Global Banking & Finance Review®
Posted on October 16, 2025
2 min readLast updated: January 21, 2026
President Trump announced plans to lower the price of Ozempic, a drug by Novo Nordisk, from $1,300 to $150, impacting diabetes and obesity treatments.
WASHINGTON (Reuters) -U.S. President Donald Trump said on Thursday that the price of Novo Nordisk's best-selling weight-loss drug would be lowered and that negotiations over price changes would be swift.
Trump made the comments during a White House event on fertility treatments and drug pricing. He was asked by reporters to identify the name of a drug that he earlier in the event said would be made less expensive.
"I was referring to Ozempic, or - I was referring to - the fat loss drug?.... They'll be much lower," Trump said.
Novo sells Ozempic for managing diabetes while Wegovy is approved for weight-loss. Both drugs contain the same active ingredient, semaglutide.
The company was not immediately available for comment.
Trump earlier said that under his administration's plans, the price of the drug would be reduced to $150 from $1,300. Ozempic has a list price of about $1,000 for a month's supply but is sold directly by Novo to cash-pay customers for $499 per month.
During the same White House event, Dr. Mehmet Oz, who runs the Centers for Medicare and Medicaid Services, said that the agency had not yet finished negotiating the price for GLP-1 drugs, which are used to treat diabetes and obesity.
Novo's Ozempic is one of the drugs that the agency has chosen for price negotiations.
(Reporting by Trevor Hunnicutt with additional reporting by Patrick Wingrove; Editing by Rami Ayyub and Caroline Humer)
Wegovy is a prescription medication specifically approved for weight loss, also containing semaglutide, the same active ingredient as Ozempic.
Explore more articles in the Headlines category
